Global Doxorubicin Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Doxorubicin Market was valued at $1.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.5% CAGR, to an estimated market size of $1.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global doxorubicin market encompasses the production and distribution of anthracycline chemotherapy agents, including conventional hydrochloride, pegylated liposomal, and lyophilized powder formulations. These agents are used as cornerstone treatments for various solid and hematologic malignancies, such as breast cancer, leukemia, lymphoma, and sarcomas, while excluding non-anthracycline cytotoxic drugs.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Doxorubicin Market in the period 2025-30:
- The rising global cancer prevalence, particularly breast and ovarian malignancies, remains the primary driver for sustained anthracycline demand.
- Increasing clinical adoption of liposomal formulations to mitigate dose-limiting cardiotoxicity and improve tumor-targeted delivery through the EPR effect.
- Integration of doxorubicin into multifaceted combination therapy regimens alongside targeted agents and immune checkpoint inhibitors to overcome drug resistance.
- Expansion of the generic drug market following patent expirations, significantly increasing treatment accessibility in emerging economies.
- A strategic shift toward personalized oncology utilizing pharmacogenomic testing to tailor dosages and optimize therapeutic efficacy.
- Growing preference for lyophilized powder formulations due to their enhanced stability, longer shelf-life, and simplified hospital procurement logistics.
- Heightened focus on sterile manufacturing standards and supply chain resilience to address frequent global shortages of critical oncology injectables.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Conventional Doxorubicin
- Liposomal Formulations
- Lyophilized Powder